LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HG-5-113-01 | 3.33 | uM | LJP5 | 3 | B08 | 72 | hr | 1476 | 1205 | 3694 | 0.3262 | -0.1225 |
| SK-BR-3 | HG-5-88-01 | 3.33 | uM | LJP6 | 1 | A20 | 72 | hr | 1476 | 2583 | 3694 | 0.6992 | 0.4989 |
| SK-BR-3 | HG-5-88-01 | 3.33 | uM | LJP6 | 2 | A20 | 72 | hr | 1476 | 2750 | 3694 | 0.7444 | 0.5742 |
| SK-BR-3 | HG-5-88-01 | 3.33 | uM | LJP6 | 3 | A20 | 72 | hr | 1476 | 2583 | 3694 | 0.6992 | 0.4989 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 1 | N14 | 72 | hr | 1476 | 3868 | 3694 | 1.0471 | 1.0784 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 2 | N14 | 72 | hr | 1476 | 4387 | 3694 | 1.1876 | 1.3125 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 3 | N14 | 72 | hr | 1476 | 4022 | 3694 | 1.0888 | 1.1479 |
| SK-BR-3 | JNK-9L | 3.33 | uM | LJP6 | 1 | K20 | 72 | hr | 1476 | 1448 | 3694 | 0.3920 | -0.0130 |
| SK-BR-3 | JNK-9L | 3.33 | uM | LJP6 | 2 | K20 | 72 | hr | 1476 | 1342 | 3694 | 0.3633 | -0.0608 |
| SK-BR-3 | JNK-9L | 3.33 | uM | LJP6 | 3 | K20 | 72 | hr | 1476 | 1350 | 3694 | 0.3655 | -0.0571 |
| SK-BR-3 | JW-7-24-1 | 3.33 | uM | LJP6 | 1 | B20 | 72 | hr | 1476 | 1941 | 3694 | 0.5254 | 0.2094 |
| SK-BR-3 | JW-7-24-1 | 3.33 | uM | LJP6 | 2 | B20 | 72 | hr | 1476 | 2002 | 3694 | 0.5420 | 0.2369 |
| SK-BR-3 | JW-7-24-1 | 3.33 | uM | LJP6 | 3 | B20 | 72 | hr | 1476 | 2227 | 3694 | 0.6029 | 0.3384 |
| SK-BR-3 | Lapatinib | 3.33 | uM | LJP6 | 1 | M20 | 72 | hr | 1476 | 1397 | 3694 | 0.3782 | -0.0360 |
| SK-BR-3 | Lapatinib | 3.33 | uM | LJP6 | 2 | M20 | 72 | hr | 1476 | 1605 | 3694 | 0.4345 | 0.0579 |
| SK-BR-3 | Lapatinib | 3.33 | uM | LJP6 | 3 | M20 | 72 | hr | 1476 | 1624 | 3694 | 0.4396 | 0.0664 |
| SK-BR-3 | LDN-193189 | 3.33 | uM | LJP5 | 1 | G02 | 72 | hr | 1476 | 1010 | 3694 | 0.2734 | -0.2105 |
| SK-BR-3 | LDN-193189 | 3.33 | uM | LJP5 | 2 | G02 | 72 | hr | 1476 | 925 | 3694 | 0.2504 | -0.2488 |
| SK-BR-3 | LDN-193189 | 3.33 | uM | LJP5 | 3 | G02 | 72 | hr | 1476 | 1231 | 3694 | 0.3332 | -0.1108 |
| SK-BR-3 | Linifanib | 3.33 | uM | LJP6 | 1 | J08 | 72 | hr | 1476 | 3638 | 3694 | 0.9848 | 0.9747 |
| SK-BR-3 | Linifanib | 3.33 | uM | LJP6 | 2 | J08 | 72 | hr | 1476 | 4337 | 3694 | 1.1740 | 1.2900 |
| SK-BR-3 | Linifanib | 3.33 | uM | LJP6 | 3 | J08 | 72 | hr | 1476 | 4211 | 3694 | 1.1399 | 1.2331 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 1 | O20 | 72 | hr | 1476 | 2642 | 3694 | 0.7152 | 0.5255 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 2 | O20 | 72 | hr | 1476 | 2950 | 3694 | 0.7986 | 0.6644 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 3 | O20 | 72 | hr | 1476 | 2934 | 3694 | 0.7943 | 0.6572 |